https://mindmedicinelaw.com/briefing/bridging-iv-ketamine-use-with-evidence-based-standards-20260709-20423The Psychedelic Journalen2026-07-09T15:05:11.697904+00:00Bridging IV Ketamine Use with Evidence-Based StandardsIV ketamine, evidence-based standards, psychiatric disorders, NMDA receptor, clinical trials, patient safety, treatment protocols, regulatory bodies, adverse effects, long-term outcomeshttps://mindmedicinelaw.com/briefing/fda-issues-ketamine-warning-amid-psychedelic-safety-concerns-20260708-20421The Psychedelic Journalen2026-07-09T15:05:25.276993+00:00FDA Issues Ketamine Warning Amid Psychedelic Safety ConcernsFDA ketamine warning, psychedelic safety concerns, clinical trials impact, regulatory scrutiny, public perception, psychedelic therapies, ketamine adverse effects, pharmaceutical distribution risks, legal implications, market dynamicshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-pilot-for-anorexia-nervosa-promising-results-20260708-20311The Psychedelic Journalen2026-07-09T15:04:57.753187+00:00Psilocybin Therapy Pilot for Anorexia Nervosa: Promising Resultspsilocybin therapy, anorexia nervosa, clinical trials, eating disorders, psychedelic research, mental health treatment, COMP360, safety and efficacy, pilot study, treatment innovationhttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-post-surgery-depression-in-breast-cancer-patients-20260708-20358The Psychedelic Journalen2026-07-09T15:04:45.864407+00:00Esketamine's Role in Reducing Post-Surgery Depression in Breast Cancer Patientsesketamine, postoperative depression, breast cancer surgery, perioperative care, randomized controlled trials, analgesic effects, depressive symptoms, clinical guidelines, evidence uncertainty, patient recoveryhttps://mindmedicinelaw.com/briefing/ketamine-use-surge-in-uk-raises-health-concerns-20260708-20106The Psychedelic Journalen2026-07-08T22:04:14.381200+00:00Ketamine Use Surge in UK Raises Health Concernsketamine use, public health, harm reduction, UK drug policy, ketamine bladder syndrome, NMDA receptors, drug misuse, therapeutic ketamine, pain management, regulatory approacheshttps://mindmedicinelaw.com/briefing/fda-targets-illegal-ketamine-sellers-amid-psychedelic-growth-20260708-20262The Psychedelic Journalen2026-07-08T22:04:03.748584+00:00FDA Targets Illegal Ketamine Sellers Amid Psychedelic GrowthFDA, ketamine, psychedelic regulation, illegal sales, mental health, compliance, clinical trials, market expansion, public health, therapeutic potentialhttps://mindmedicinelaw.com/briefing/dea-s-proposed-schedule-i-classification-for-tianeptine-20260708-19964The Psychedelic Journalen2026-07-08T15:04:35.578599+00:00DEA's Proposed Schedule I Classification for Tianeptinetianeptine, DEA, Schedule I, controlled substances, drug regulation, research restrictions, market impact, substance abuse, psychedelic research, legal implicationshttps://mindmedicinelaw.com/briefing/brain-based-depression-subtypes-new-study-insights-20260707-20313The Psychedelic Journalen2026-07-09T15:05:51.401049+00:00Brain-Based Depression Subtypes: New Study Insightsmajor depressive disorder, brain-based subtypes, neurotransmitter systems, cortical thickness, dopamine transporter, histamine receptor H3, personalized treatment, psychiatric research, neuroimaging, mental healthhttps://mindmedicinelaw.com/briefing/slc36a1-transporter-structure-implications-for-cns-drug-delivery-20260707-20361The Psychedelic Journalen2026-07-09T15:05:37.703784+00:00SLC36A1 Transporter Structure: Implications for CNS Drug DeliverySLC36A1 transporter, CNS drug delivery, cryo-EM structure, amino-acid transport, oral drug design, neuroscience research, proton-coupled transport, blood-brain barrier, pharmacokinetics, drug absorptionhttps://mindmedicinelaw.com/briefing/gut-microbiota-and-cognitive-impairment-in-mdd-new-insights-from-china-20260707-20042The Psychedelic Journalen2026-07-08T22:04:41.128967+00:00Gut Microbiota and Cognitive Impairment in MDD: New Insights from Chinagut microbiota, oxidative stress, cognitive impairment, major depressive disorder, mental health research, therapeutic strategies, China pilot study, inflammation, psychobiotics, brain-gut axishttps://mindmedicinelaw.com/briefing/2-adrenergic-receptor-s-impact-on-mdma-psilocybin-effects-20260707-20102The Psychedelic Journalen2026-07-08T22:04:31.948415+00:00α(2)-Adrenergic Receptor's Impact on MDMA, Psilocybin Effectsα(2)-adrenergic receptor, 5-HT(2A) receptor, MDMA effects, psilocybin effects, psychedelic therapy, receptor interactions, clinical trials, neuroscience, safety profiles, therapeutic strategieshttps://mindmedicinelaw.com/briefing/biopsychosocial-insights-into-stress-induced-psychopathology-20260707-20015The Psychedelic Journalen2026-07-08T22:04:22.039730+00:00Biopsychosocial Insights into Stress-Induced Psychopathologystress-induced psychopathology, biopsychosocial model, anxiety disorders, neurobiological factors, genetic influences, personalized interventions, PTSD symptom fluctuation, bioenergetic signatures, complex systems, psychiatric disordershttps://mindmedicinelaw.com/briefing/2-adrenergic-receptor-s-role-in-modulating-mdma-psilocybin-effects-20260707-19995The Psychedelic Journalen2026-07-08T15:05:05.916386+00:00α2-Adrenergic Receptor's Role in Modulating MDMA, Psilocybin Effectsα2-adrenergic receptors, MDMA effects, psilocybin modulation, psychedelic therapies, serotonin receptors, norepinephrine, clinical trials, receptor interactions, therapeutic development, side effects reductionhttps://mindmedicinelaw.com/briefing/ayahuasca-s-potential-in-depression-research-implications-and-challenges-20260707-20075The Psychedelic Journalen2026-07-08T15:04:54.322075+00:00Ayahuasca's Potential in Depression Research: Implications and Challengesayahuasca, depression research, treatment-resistant depression, clinical trials, serotonin receptors, pharmacological profile, psychedelic therapy, DMT, mental health, regulatory frameworkshttps://mindmedicinelaw.com/briefing/ketamine-s-cognitive-effects-in-trd-new-findings-20260707-20043The Psychedelic Journalen2026-07-08T15:04:45.609350+00:00Ketamine's Cognitive Effects in TRD: New Findingsketamine, treatment-resistant depression, cognitive function, personalized treatment, clinical trials, mental healthhttps://mindmedicinelaw.com/briefing/psychedelic-treatment-for-postpartum-depression-new-horizons-20260707-19950The Psychedelic Journalen2026-07-07T22:05:06.034539+00:00Psychedelic Treatment for Postpartum Depression: New Horizonspsychedelic treatment, postpartum depression, mental health, clinical trials, neuroscience, public health, serotonin pathways, FDA regulations, neuroplasticity, emotional processinghttps://mindmedicinelaw.com/briefing/biomarker-guided-antidepressant-trial-for-mdd-insights-implications-20260706-20044The Psychedelic Journalen2026-07-08T22:04:58.147974+00:00Biomarker-Guided Antidepressant Trial for MDD: Insights & Implicationsbiomarker-guided treatment, major depressive disorder, bupropion, sertraline, precision medicine, clinical trial, antidepressant response, personalized treatment, biobehavioral markers, mental health researchhttps://mindmedicinelaw.com/briefing/psilocibin-safety-review-multi-organ-effects-under-scrutiny-20260706-20032The Psychedelic Journalen2026-07-08T15:05:24.199019+00:00Psilocibin Safety Review: Multi-Organ Effects Under Scrutinypsilocibin safety, multi-organ effects, serotonergic hallucinogen, treatment-resistant depression, clinical trials, psychedelic research, biologically plausible mechanisms, safety signals, therapeutic applications, regulatory guidelineshttps://mindmedicinelaw.com/briefing/depression-in-neurodegenerative-diseases-new-treatment-insights-20260706-19997The Psychedelic Journalen2026-07-08T15:05:15.035612+00:00Depression in Neurodegenerative Diseases: New Treatment Insightsdepression, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, emerging therapies, neurobiological mechanisms, clinical trials, precision psychiatry, treatment resistance, brain stimulationhttps://mindmedicinelaw.com/briefing/tfus-in-schizophrenia-evidence-mechanisms-and-future-directions-20260706-19872The Psychedelic Journalen2026-07-07T22:05:15.773514+00:00tFUS in Schizophrenia: Evidence, Mechanisms, and Future Directionstranscranial focused ultrasound stimulation, tFUS, schizophrenia treatment, neuromodulation, clinical trials, non-invasive therapy, brain networks, neuroscience researchhttps://mindmedicinelaw.com/briefing/ketamine-s-eeg-effects-vary-in-tr-mdd-tr-ptsd-tr-ocd-20260706-19884The Psychedelic Journalen2026-07-07T22:04:31.140623+00:00Ketamine's EEG Effects Vary in TR-MDD, TR-PTSD, TR-OCDketamine, EEG, treatment-resistant depression, post-traumatic stress disorder, obsessive-compulsive disorder, personalized psychiatry, psychedelic therapy, neural mechanisms, clinical trials, psychiatric carehttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-trd-kads-study-extension-insights-20260706-19885The Psychedelic Journalen2026-07-07T22:04:16.584922+00:00Subcutaneous Ketamine for TRD: KADS Study Extension Insightssubcutaneous ketamine, treatment-resistant depression, KADS study, clinical trials, depression treatment, psychedelic research, mental health, long-term effects, safety profile, antidepressant therapyhttps://mindmedicinelaw.com/briefing/psilocybin-mdma-efficacy-for-ptsd-trd-in-systematic-review-20260705-19840The Psychedelic Journalen2026-07-07T22:04:40.723595+00:00Psilocybin & MDMA: Efficacy for PTSD & TRD in Systematic Reviewpsilocybin, MDMA, PTSD, treatment-resistant depression, systematic review, clinical trials, psychedelic therapy, mental health, Phase 3 trials, regulatory implicationshttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-ptsd-aud-new-clinical-trial-20260701-19858The Psychedelic Journalen2026-07-07T22:04:53.768037+00:00MDMA-Assisted Therapy for PTSD & AUD: New Clinical TrialMDMA-assisted therapy, PTSD treatment, alcohol use disorder, clinical trial, integrated exposure therapy, mental health research